Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
|Articles|June 2, 2019
- Pharmaceutical Technology-06-02-2019
- Volume 43
- Issue 6
Sanitary Tumble Blenders
The Ross VCB-0.25 Tumble Blender is suited for specialty blends with extremely minor active components and additives.
The Ross VCB-0.25 Tumble Blender is suited for specialty blends with extremely minor active components and additives. Suitable for processing high value and delicate applications, the blender is often provided in a sanitary all-stainless-steel construction and imparts gentle agitation. Options for process optimization include vacuum design, heating jacket, intensifier bar for deagglomerating clumps, and custom programmable logic controller. According to the company, the vessel’s characteristic v-shaped geometry facilitates 100% product discharge. Available working capacities range from a quarter cubic foot to 100 cubic feet.
Articles in this issue
over 7 years ago
Hovione Technology Develops Blister-Based Inhalerover 7 years ago
Enabling Technologies Advance Poorly Soluble Highly Potent APIsover 7 years ago
Pharma Facilities Still Have a Lot to Learnover 7 years ago
Filling the Early Intermediate Security Gapover 7 years ago
As Easy as ABC?over 7 years ago
Regulating Cannabis-Based Medicines in Europeover 7 years ago
Supply Chain Risk and Security Maturity Evolutionover 7 years ago
On the Right Trackover 7 years ago
Looking Beyond the Solubility Horizonover 7 years ago
Enhancing Bioavailability with Hot-Melt ExtrusionRelated to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.